Epilepsy Research Reagents

Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, affecting over 50 million people worldwide. Pathogenesis involves excitatory/inhibitory imbalance through GABAergic hypofunction, glutamatergic hyperexcitation, and ion channel mutations (SCN1A, KCNA1). mTOR pathway hyperactivation underlies epilepsy in tuberous sclerosis complex and focal cortical dysplasia, while autoimmune epilepsies targeting LGI1 and NMDA receptors represent an expanding clinical category.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Epilepsy Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key epilepsy and seizure disorder research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

GABA-A Receptor — GABA-A receptors mediate fast inhibitory neurotransmission, and their dysfunction contributes to seizure susceptibility. Anti-GABA-A receptor subunit antibodies support inhibitory synapse studies and benzodiazepine mechanism research.
→ Browse GABA receptor antibodies

mTOR / TSC1 / TSC2 — mTOR hyperactivation drives epileptogenesis in TSC and focal cortical dysplasia. Anti-mTOR and anti-phospho-S6 antibodies enable pathway activation assessment and everolimus/rapamycin treatment response studies.
→ Browse mTOR pathway antibodies

LGI1 — Anti-LGI1 autoantibodies cause autoimmune limbic encephalitis with faciobrachial dystonic seizures. Recombinant LGI1 proteins and anti-LGI1 antibodies support autoimmune epilepsy diagnostic assay development.
→ Browse LGI1 antibodies & proteins

References

1. Thijs RD, et al. Epilepsy in adults. Lancet. 2019;393(10172):689-701. DOI

2. Citraro R, et al. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333-343. DOI

3. Irani SR, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-2748. DOI